- testing |
| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 31 Oct 2025 | 24 Oct 2025 |
| Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/10/2025 inter alia to consider and approve Intimation regarding Board Meeting under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 Outcome of Board Meeting - Unaudited Financial Results (Consolidated & Standalone) for the quarter and half year ended September 30, 2025 (As Per BSE Announcement Dated on:31.10.2025) | ||
| Board Meeting | 29 Jul 2025 | 23 Jul 2025 |
| Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2025 inter alia to consider and approve This is to inform you that a meeting of Board of Directors of the Company is scheduled to be held on Tuesday July 29 2025 to consider and approve the un-audited financial results (standalone and consolidated) of the Company for the quarter ended June 30 2025 amongst other matters. Further as per provisions of the Companys Code of Conduct for Prohibition of Insider Trading trading window for Designated Persons of the Company is closed from July 1 2025 and shall open after 48 hrs post declaration of financial results by the Company. Financial Results (Consolidated & Standalone) for the quarter ended June 30, 2025 Allotment of shares under the ESOP Scheme (As Per BSE Announcement Dated on :29.07.2025) | ||
| Board Meeting | 22 May 2025 | 15 May 2025 |
| Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/05/2025 inter alia to consider and approve Pursuant to Regulation 29(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that a meeting of Board of Directors of the Company is scheduled to be held on Thursday May 22 2025 inter alia: 1) To consider and approve the audited financial results (standalone and consolidated) of the Company for the quarter and financial year ended March 31 2025; and 2) To consider and recommend final dividend if any on the equity shares of the Company for the financial year ended March 31 2025. Further as per the provisions of the Companys Code of Conduct for Prohibition of Insider Trading trading window for designated persons of the Company has been closed from April 1 2025 and shall open after 48 hrs post declaration of financial results of the Company. Recommendation of final dividend of Rs. 4/- per equity share of Rs. 10 each (at the rate of 40%) for FY25. Outcome of Board Meeting of the Company held on May 22, 2025 Appointment of Secretarial Auditor Update on Promoters Reclassification Request (As Per BSE Announcement Dated on 22.05.2025) | ||
| Board Meeting | 19 Mar 2025 | 19 Mar 2025 |
| Proposed de-merger of Identified Business of Arco Lab Private Limited, a wholly owned subsidiary of the Company. | ||
| Board Meeting | 30 Jan 2025 | 24 Jan 2025 |
| Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2025 inter alia to consider and approve This is to inform you that meeting of Board of Directors of the Company is scheduled to be held on Thursday January 30 2025 to consider and approve the un-audited financial results (standalone and consolidated) of the Company for the quarter and nine months ended December 31 2024 amongst other matters. Further as per provisions of the Companys Code of Conduct for Prohibition of Insider Trading trading window for Designated Persons of the Company is closed from January 1 2025 and shall open after 48 hrs post declaration of un-audited financial results by the Company. Outcome of Board Meeting - Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2024. Appointment of Ms. Mukta Arora (DIN: 07225715) as Independent Director of the Company effective February 1, 2025. Change in designation of Mr. Arun Kumar (DIN: 00084845) from Executive Chairperson to Non-Executive Chairperson of the Company effective April 5, 2025. Change in Registered office of the Company (As Per BSE Announcement dated on 30.01.2025) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.